Boston, MA, 04/03/2014 (usastockreports) – Response Genetics, Inc. (NASDAQ:RGDX), a clinical laboratory solely focused on the study of in the U.S., made an announcement on April 3, 2014 that the firm has got into agreements with six new health plans and these plans are distributed across ten states. These agreements would increase the total contracted membership of the firm to about 174 million people.
The new agreement signed by the firm includes ‘Blue cross blue shield’ contract in the areas of West Virginia, Pennsylvania, Iowa, Arizona, Delaware and South Dakota. Response Genetics, Inc. (NASDAQ:RGDX) also signed agreements with a Commercial health plan, which would be covering 2 states in the north-east part of the U.S. and an independent Physician Association which would also cover 2 states in the North-West part of the U.S.
These new partnerships of the firm with six network providers will contribute in the growth of various programs run by it. These agreements have enabled RGDX to be connected with 13 BCBS (i.e. Blue cross blue shield) health plans across the country. These associations are now being able to connect 23 million subscribers of BCBS to RGDX services directly. Some of the important contracts of RGDX with BCBS are BCBS of Illinois, CareFirst BCBS of North Virginia, Washington and Maryland and as well as BCBS of California.
RGDX’s current work
RGDX is currently working on therapy selection for cancer patients having colon, melanoma, lung, thyroid and gastric cancer. These studies done by RGDX provide the physicians treating the patients with some crucial information regarding the patient’s tumor as well as the best suitable therapy for that kind of tumor. And by signing contracts with these BCBS health plans, Response Genetics, Inc. (NASDAQ:RGDX) is aiming to improve these services by providing individual tailored medicines to its members.
These collaborations would help the firm to treat more and more cancer patients across the nation in a more effective manner.